Elicio Therapeutics, Inc. (ELTX) shareholders
Close on Nov 17, 2026Market cap $37.58MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Yekaterina Chudnovsky Joint filing with Gkcc, LLC (48.00%) | 9,764,864 | 48.00% | 13D (active) amendment | Jun 3, 2025 |
| Moti Investments LLC | 1,408,892 | 6.10% | 13G (passive) | Jul 1, 2026 |
| Gakasa Holdings, LLC Joint filing with Knoll Capital Management, LLC (5.30%), Fred Knoll (5.30%) | 1,211,957 | 5.30% | 13G (passive) amendment | Jul 1, 2026 |
| Knoll Capital Management, LLC Joint filing with Fred Knoll (5.20%), Gakasa Holdings, LLC (5.20%) | 630,915 | 5.20% | 13G (passive) | Jan 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ELTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 1,211,957 | 4.61% | $4.74M | +581,042 | 2.64% |
| BlackRock, Inc. | 766,005 | 2.91% | $3.00M | +715,408 | 0.00% |
| Vanguard Capital Management LLC | 572,151 | 2.18% | $2.24M | +53,513 | 0.00% |
| Geode Capital Management, LLC | 311,354 | 1.18% | $1.22M | +176,190 | 0.00% |
| State Street Corp | 179,420 | 0.68% | $701.53K | +128,800 | 0.00% |
| Northern Trust Corp | 130,162 | 0.50% | $508.93K | +70,428 | 0.00% |
| Ikarian Capital, LLC | 100,000 | 0.38% | $391.00K | New | 0.04% |
| Vanguard Portfolio Management LLC | 88,905 | 0.34% | $347.62K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 88,062 | 0.34% | $344.32K | +18,873 | 0.00% |
| Alliancebernstein L.P. | 81,280 | 0.31% | $317.81K | New | 0.00% |
| UBS Group AG | 40,419 | 0.15% | $158.04K | +6,650 | 0.00% |
| Charles Schwab Investment Management Inc | 31,706 | 0.12% | $123.97K | New | 0.00% |
| Boothbay Fund Management, LLC | 30,690 | 0.12% | $120.00K | New | 0.00% |
| Morgan Stanley | 25,546 | 0.10% | $99.89K | −6,858 | 0.00% |
| Leonteq Securities AG | 20,000 | 0.08% | $78.20K | New | 0.00% |
| Nuveen, LLC | 17,888 | 0.07% | $69.94K | New | 0.00% |
| Citigroup Inc | 17,726 | 0.07% | $69.31K | New | 0.00% |
| Bank of New York Mellon Corp | 15,884 | 0.06% | $62.11K | New | 0.00% |
| New York State Common Retirement Fund | 14,200 | 0.05% | $55.52K | New | 0.00% |
| Meyer Handelman Co | 13,899 | 0.05% | $54.35K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 48 | 4M | 14.9% | 24 / 14 | 3 / 23 | 2M | 1M |
| Q1 2026 | 47 | 3M | 10.0% | 19 / 13 | 6 / 7 | 1M | 0M |
| Q4 2025 | 37 | 2M | 7.9% | 13 / 10 | 5 / 4 | 0M | 0M |
| Q3 2025 | 28 | 2M | 7.3% | 10 / 9 | 2 / 3 | 1M | 0M |
| Q2 2025 | 21 | 1M | 5.5% | 3 / 5 | 5 / 6 | 0M | 0M |
| Q1 2025 | 24 | 2M | 6.1% | 9 / 8 | 2 / 2 | 1M | 0M |
| Q4 2024 | 17 | 0M | 1.7% | 2 / 2 | 7 / 3 | 0M | 0M |
| Q3 2024 | 18 | 0M | 1.9% | 4 / 6 | 1 / 4 | 0M | 0M |
| Q2 2024 | 20 | 1M | 2.5% | 5 / 7 | 2 / 3 | 0M | 0M |
| Q1 2024 | 18 | 0M | 1.5% | 4 / 5 | 2 / 4 | 0M | 0M |
| Q4 2023 | 18 | 0M | 1.3% | 2 / 6 | 4 / 2 | 0M | 0M |
| Q3 2023 | 18 | 0M | 1.3% | 3 / 6 | 3 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
39 funds held ELTX in Q2 2026, 77% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ELTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 415,401 | 1.58% | $1.62M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 318,753 | 1.21% | $1.25M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 143,596 | 0.55% | $561.46K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 139,731 | 0.53% | $391.25K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 121,695 | 0.46% | $475.83K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 58,434 | 0.22% | $668.48K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 43,717 | 0.17% | $170.93K | 0.01% | Jun 30, 2026 |
| EQ/Small Company Index Portfolio | 40,640 | 0.15% | $158.90K | 0.01% | Jun 30, 2026 |
| EQ/AB Small Cap Growth Portfolio | 40,640 | 0.15% | $158.90K | 0.01% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 31,706 | 0.12% | $88.78K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 29,434 | 0.11% | $115.09K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 21,289 | 0.08% | $243.55K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 17,888 | 0.07% | $50.09K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 16,617 | 0.06% | $190.10K | 0.00% | May 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 16,449 | 0.06% | $64.32K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert Connelly | CEO, President and Director | 120,570 | 0.46% | Jul 17, 2026 |
| Peter DeMuth | Chief Scientific Officer | 21,543 | 0.08% | Jul 17, 2026 |
| Christopher Haqq | See Remarks | 57,381 | 0.22% | Jul 17, 2026 |
| Preetam Shah | See Remarks | 24,000 | 0.09% | Jul 17, 2026 |
| Jay Venkatesan | Director | 180,534 | 0.69% | Sep 2, 2026 |
| Karen J. Wilson | Director | 18,718 | 0.07% | Sep 2, 2026 |
| Robert R. Ruffolo | Director | – | – | Sep 2, 2026 |
| Yekaterina Chudnovsky | Director, 10% owner | 5,416,212 | 20.61% | Sep 2, 2026 |
| Allen Nissenson | Director | 9,383 | 0.04% | Sep 2, 2026 |
| Carol Gail Ashe | Director | – | – | Sep 2, 2026 |
| Julian Adams | Director | – | – | Sep 2, 2026 |
| Gkcc, Llc | 10% owner | 1,915,639 | 7.29% | Jun 4, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Peter DeMuth Chief Scientific Officer | Feb 2, 2026 | Award | +20,800 | – | – | 21,543 |
| Christopher Haqq See Remarks | Feb 2, 2026 | Award | +25,400 | – | – | 57,381 |
| Robert Connelly CEO, President and Director | Feb 2, 2026 | Award | +73,600 | – | – | 120,570 |
| Preetam Shah See Remarks | Feb 2, 2026 | Award | +24,000 | – | – | 24,000 |
| Peter DeMuth Chief Scientific Officer | Dec 9, 2025 | Option exercise | +362 | $4.41 | $1.60K | 743 |
| Yekaterina Chudnovsky Director, 10% owner | Mar 5, 2025 | Conversion | +3,500,573 | $5.81 | $20.34M | 5,416,212 |
| Peter DeMuth Chief Scientific Officer | Dec 16, 2024 | Option exercise | +381 | $4.41 | $1.68K | 381 |
| Jay Venkatesan Director | Nov 26, 2024 | Option exercise | +50,000 | $0.01 | $500 | 179,581 |
| Gkcc, Llc 10% owner | Dec 22, 2023 | Buy | +1,213,000 | $5.81 | $7.05M | 1,915,639 |
| Itzhak Goldberg Director | Jul 1, 2022 | Tax withholding | −32,082 | $1.12 | $35.93K | 1,687,986 |
| Jay Venkatesan See Remarks, Director | May 25, 2022 | Buy | +11,313 | $1.25 | $14.14K | 1,891,947 |
| Jay Venkatesan See Remarks, Director | May 24, 2022 | Buy | +32,200 | $1.24 | $39.93K | 1,721,457 |
| Jay Venkatesan See Remarks, Director | May 20, 2022 | Buy | +50,000 | $1.23 | $61.50K | 1,689,257 |
| Allen Nissenson Director | May 20, 2022 | Buy | +2,037 | $1.18 | $2.40K | 9,383 |
| Allen Nissenson Director | May 19, 2022 | Buy | +7,346 | $1.16 | $8.52K | 7,346 |
| Jay Venkatesan See Remarks, Director | Dec 28, 2021 | Buy | +210,337 | $2.66 | $559.50K | 1,639,257 |
| Jay Venkatesan See Remarks, Director | Dec 27, 2021 | Buy | +66,907 | $2.55 | $170.61K | 1,428,920 |
| Jay Venkatesan See Remarks, Director | Dec 20, 2021 | Buy | +3,527 | $2.54 | $8.96K | 1,362,013 |
| John F. Neylan See Remarks | Dec 20, 2021 | Sale(10b5-1 plan) | −358 | $2.62 | $938 | 35,136 |
| Jay Venkatesan See Remarks, Director | Dec 17, 2021 | Buy | +13,742 | $2.54 | $34.90K | 1,358,486 |
| Jay Venkatesan See Remarks, Director | Dec 16, 2021 | Buy | +27,883 | $2.55 | $71.10K | 1,344,744 |
| Jay Venkatesan See Remarks, Director | Dec 15, 2021 | Buy | +77,604 | $2.41 | $187.03K | 1,316,861 |
| Gregory S. Curhan See Remarks | Dec 15, 2021 | Buy | +4,000 | $2.37 | $9.48K | 4,000 |
| Jennifer J. Rhodes See Remarks | Dec 14, 2021 | Sale(10b5-1 plan) | −451 | $2.42 | $1.09K | 30,399 |
| Itzhak Goldberg See Remarks, Director | Dec 6, 2021 | Sale(10b5-1 plan) | −32,118 | $3.35 | $107.60K | 1,720,068 |
| Itzhak Goldberg See Remarks, Director | Dec 3, 2021 | Sale(10b5-1 plan) | −40,215 | $3.39 | $136.33K | 1,752,186 |
| Itzhak Goldberg See Remarks, Director | Dec 2, 2021 | Sale(10b5-1 plan) | −38,800 | $3.51 | $136.19K | 1,792,401 |
| Itzhak Goldberg See Remarks, Director | Dec 1, 2021 | Sale(10b5-1 plan) | −38,867 | $3.54 | $137.59K | 1,831,201 |
| John F. Neylan See Remarks | Nov 18, 2021 | Sale(10b5-1 plan) | −374 | $4.13 | $1.54K | 35,494 |
| Itzhak Goldberg See Remarks | Nov 16, 2021 | Sale(10b5-1 plan) | −38,495 | $4.26 | $163.99K | 1,870,068 |
| Itzhak Goldberg See Remarks | Nov 15, 2021 | Sale(10b5-1 plan) | −111,505 | $4.17 | $464.98K | 1,908,563 |
| Jennifer J. Rhodes See Remarks | Nov 15, 2021 | Sale(10b5-1 plan) | −433 | $4.40 | $1.91K | 30,850 |
| John F. Neylan See Remarks | Oct 18, 2021 | Sale(10b5-1 plan) | −373 | $8.62 | $3.22K | 35,868 |
| Jennifer J. Rhodes See Remarks | Oct 14, 2021 | Sale(10b5-1 plan) | −430 | $8.65 | $3.72K | 31,283 |
| John F. Neylan See Remarks | Sep 20, 2021 | Sale(10b5-1 plan) | −376 | $10.07 | $3.79K | 36,241 |
| Jennifer J. Rhodes See Remarks | Sep 14, 2021 | Sale(10b5-1 plan) | −430 | $10.64 | $4.58K | 31,713 |
| Llc Eisa-Abc 10% owner | Aug 31, 2021 | Other | −913,659 | – | – | 2,740,978 |
| John F. Neylan See Remarks | Aug 18, 2021 | Sale(10b5-1 plan) | −381 | $9.03 | $3.44K | 36,617 |
| Jennifer J. Rhodes See Remarks | Aug 16, 2021 | Sale(10b5-1 plan) | −445 | $10.68 | $4.75K | 32,143 |
| Jennifer J. Rhodes See Remarks | Jul 21, 2021 | Sale(10b5-1 plan) | −432 | $10.94 | $4.73K | 32,588 |
| John F. Neylan See Remarks | Jul 21, 2021 | Sale(10b5-1 plan) | −365 | $10.98 | $4.01K | 36,998 |
| Jennifer J. Rhodes See Remarks | Jul 14, 2021 | Sale(10b5-1 plan) | −431 | $11.01 | $4.75K | 32,589 |
| Jay Venkatesan See Remarks, Director | Jun 24, 2021 | Tax withholding | −41,091 | $13.78 | $566.23K | 1,239,257 |
| Itzhak Goldberg See Remarks | Jun 24, 2021 | Tax withholding | −47,410 | $13.78 | $653.31K | 2,020,068 |
| John F. Neylan See Remarks | Jun 18, 2021 | Sale(10b5-1 plan) | −366 | $13.20 | $4.83K | 37,363 |
| Jennifer J. Rhodes See Remarks | Jun 14, 2021 | Sale(10b5-1 plan) | −427 | $13.27 | $5.67K | 33,020 |
| John F. Neylan See Remarks | May 18, 2021 | Sale(10b5-1 plan) | −363 | $13.91 | $5.05K | 37,729 |
| Jennifer J. Rhodes See Remarks | May 14, 2021 | Sale(10b5-1 plan) | −440 | $13.92 | $6.12K | 33,447 |
| John F. Neylan See Remarks | Apr 19, 2021 | Sale(10b5-1 plan) | −381 | $13.55 | $5.16K | 38,092 |
| Jennifer J. Rhodes See Remarks | Apr 15, 2021 | Sale | −399 | $15.01 | $5.99K | 33,887 |
| John F. Neylan See Remarks | Mar 17, 2021 | Sale | −442 | $19.13 | $8.46K | 38,453 |
| Jennifer J. Rhodes See Remarks | Mar 13, 2021 | Sale | −499 | $20.45 | $10.20K | 34,286 |
| Jennifer J. Rhodes See Remarks | Feb 13, 2021 | Sale | −457 | $19.54 | $8.93K | 34,785 |
| Victor F. Ganzi Director | Feb 9, 2021 | Sale | −246,720 | $16.00 | $3.95M | 823,117 |
| Victor F. Ganzi Director | Feb 9, 2021 | Option exercise | +614,310 | $6.43 | $3.95M | 1,069,837 |
| Jay Venkatesan See Remarks, Director | Feb 9, 2021 | Conversion | +262 | $11.57 | $3.03K | 1,439,525 |
| Jay Venkatesan See Remarks, Director | Feb 9, 2021 | Sale | −159,177 | $16.00 | $2.55M | 1,367,263 |
| Jay Venkatesan See Remarks, Director | Feb 9, 2021 | Option exercise | +396,329 | $6.43 | $2.55M | 1,598,440 |
| Victor F. Ganzi Director | Feb 9, 2021 | Sale | −246,720 | $16.00 | $3.95M | 576,397 |
| Victor F. Ganzi Director | Feb 9, 2021 | Option exercise | +367,590 | $6.43 | $2.36M | 823,117 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Elicio Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,294 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?